Suchergebnisse

Contribuição preliminar aos estudos da erosão no município de Uberlândia-MG: avaliação sob o aspecto de infiltração da água em ensaios in situ com o uso de infiltrômetro de duplo cilindro

The paper highlights gender as a main force in the distribution of power and resources in the global economy. As more Latin American women join the labor force, men partake of a two-fold experience; while some are making gains as technicians and professionals, many more are working in jobs with characteristics formerly associated with female employment. As workforces reconfigure on the basis of gender, men and women confront new dilemmas about their proper roles in society.

Darstellung der Bedeutung der Fertigungsbetriebe multinationaler und US-amerikanischer Konzerne im mexikanischen Grenzraum zu den USA für den regionalen Arbeitsmarkt. Kennzeichnung der Arbeitsbedingungen insbesondere für Frauen und Bericht über ihre Organisation COMO zur Erziehung und Selbsthilfe, zur Alphabetisierung und zur Aneignung zusätzlicher beruflicher Qualifikationen mit Unterstützung der öffentlichen Verwaltung

O presente estudo teve como objetivo analisar como a criatividade tem sido apropriada nos estudos de gestão dos últimos cinco anos por meio de uma revisão integrativa de literatura. A revisão integrativa foi realizada com o apoio da plataforma SPELL, utilizando os seguintes filtros: Palavra-chave: criatividade; Período da publicação: janeiro de 2015 a janeiro de 2020; Tipo de documento: artigo; Idioma: português. Esta busca resultou num quantitativo de 32 (trinta e duas) publicações. Com a leitura acurada dos resumos, foram excluídos 8 (oito) artigos do corpus, pois tratavam de temas que não levavam em consideração a prática da criatividade nas organizações, totalizando 24 (vinte e quatro) artigos. Realizou-se a leitura do corpus e como resultados foram criados quadros que correspondem às matrizes de síntese das categorias temáticas, delimitadas como: "Relações entre criatividade e inovação"; "Métricas para aferir a criatividade"; Criatividade como insumo para a economia criativa"; e "Outras perspectivas emergentes". Percebe-se uma heterogeneidade temática dos estudos do corpus, tendo-se como recomendações que futuros estudos possam abordar a inter-relação entre a criatividade e a inovação, elementos da gestão da criatividade, abordagens qualitativas como alternativas às métricas e a possibilidade de estudos em contextos diferenciados, como negócios sociais, empreendimentos turísticos e organizações públicas.

This article provides a reflective critique of the process undertaken to pilot the Carnegie Community Engagement Framework in Ireland between 2015 and 2016. Of particular interest to the authors is the cultural specificity of employing a US-centric self-assessment data capturing tool in a heterogeneous Irish context. Taking the reader through from conception of the idea to its execution and post-pilot reflections, we examine the cultural appropriateness and translatability of the tool to Irish higher education. To frame the discussion of the process, we employ the concept of a community of practice, as defined by Wenger (1998). This was adopted to promote a culture of collaboration in an ever-growing neoliberal system that promotes competition between institutions, rather than facilitating their co-construction of knowledge. In the analysis, we demonstrate how forming this community of practice allowed for a cohesive assessment of the challenges and opportunities that arose through the pilot process. This was particularly important since each participating institution had different motivations for engaging with the pilot. Reflecting with some distance, we consider the value that comes from operating as a community of practice, as well as some shortcomings that we identified as specific to this pilot.

Background The use of levothyroxine to treat subclinical hypothyroidism is controversial. We aimed to determine whether levothyroxine provided clinical benefits in older persons with this condition. Methods We conducted a double-blind, randomized, placebo-controlled, parallel-group trial involving 737 adults who were at least 65 years of age and who had persisting subclinical hypothyroidism (thyrotropin level, 4.60 to 19.99 mIU per liter; free thyroxine level within the reference range). A total of 368 patients were assigned to receive levothyroxine (at a starting dose of 50 μg daily, or 25 μg if the body weight was <50 kg or the patient had coronary heart disease), with dose adjustment according to the thyrotropin level; 369 patients were assigned to receive placebo with mock dose adjustment. The two primary outcomes were the change in the Hypothyroid Symptoms score and Tiredness score on a thyroid-related quality-of-life questionnaire at 1 year (range of each scale is 0 to 100, with higher scores indicating more symptoms or tiredness, respectively; minimum clinically important difference, 9 points). Results The mean age of the patients was 74.4 years, and 396 patients (53.7%) were women. The mean (±SD) thyrotropin level was 6.40±2.01 mIU per liter at baseline; at 1 year, this level had decreased to 5.48 mIU per liter in the placebo group, as compared with 3.63 mIU per liter in the levothyroxine group (P<0.001), at a median dose of 50 μg. We found no differences in the mean change at 1 year in the Hypothyroid Symptoms score (0.2±15.3 in the placebo group and 0.2±14.4 in the levothyroxine group; between-group difference, 0.0; 95% confidence interval [CI], -2.0 to 2.1) or the Tiredness score (3.2±17.7 and 3.8±18.4, respectively; between-group difference, 0.4; 95% CI, -2.1 to 2.9). No beneficial effects of levothyroxine were seen on secondary-outcome measures. There was no significant excess of serious adverse events prespecified as being of special interest. Conclusions Levothyroxine provided no apparent benefits in older persons with subclinical hypothyroidism. (Funded by European Union FP7 and others; TRUST ClinicalTrials.gov number, NCT01660126 .).

BACKGROUND: The use of levothyroxine to treat subclinical hypothyroidism is controversial. We aimed to determine whether levothyroxine provided clinical benefits in older personswith this condition. METHODS: We conducted a double-blind, randomized, placebo-controlled, parallel-group trial involving 737 adults who were at least 65 years of age and who had persisting subclinical hypothyroidism (thyrotropin level, 4.60 to 19.99 mIU per liter; free thyroxine level within the reference range). A total of 368 patients were assigned to receive levothyroxine (at a starting dose of 50 μg daily, or 25 μg if the body weight was <50 kg or the patient had coronary heart disease), with dose adjustment according to thethyrotropin level; 369 patients were assigned to receive placebo with mock dose adjustment. The two primary outcomes were the change in the Hypothyroid Symptomsscore and Tiredness score on a thyroid-related quality-of-life questionnaire at 1 year (range of each scale is 0 to 100, with higher scores indicating more symptoms or tiredness, respectively; minimum clinically important difference, 9 points). RESULTS: The mean age of the patients was 74.4 years, and 396 patients (53.7%) were women.The mean (±SD) thyrotropin level was 6.40±2.01 mIU per liter at baseline; at 1 year,this level had decreased to 5.48 mIU per liter in the placebo group, as compared with3.63 mIU per liter in the levothyroxine group (P<0.001), at a median dose of 50 μg. We found no differences in the mean change at 1 year in the Hypothyroid Symptomsscore (0.2±15.3 in the placebo group and 0.2±14.4 in the levothyroxine group; between-group difference, 0.0; 95% confidence interval [CI], −2.0 to 2.1) or the Tirednessscore (3.2±17.7 and 3.8±18.4, respectively; between-group difference, 0.4; 95% CI,−2.1 to 2.9). No beneficial effects of levothyroxine were seen on secondary-outcome measures. There was no significant excess of serious adverse events prespecified as being of special interest. CONCLUSIONS: Levothyroxine provided no apparent benefits in older persons with subclinical hypothyroidism. (Funded by European Union FP7 and others; TRUST ClinicalTrials.govnumber, NCT01660126.)